Imiquimod

證據等級: L5

預測適應症: 10 個

Imiquimod: From Actinic Keratosis / Superficial Basal Cell Carcinoma to Pre-Malignant Neoplasm

One-Sentence Summary

Imiquimod is a topical Toll-like receptor 7 (TLR7) agonist, established for actinic keratosis, superficial basal cell carcinoma, and external genital warts. The TxGNN model predicts it may be effective more broadly for Pre-Malignant Neoplasm, with 19 clinical trials and 9 publications — including two Cochrane systematic reviews — currently supporting this direction, though the drug is not marketed in Finland.

Quick Overview

Item	Content
Original Indication	Actinic keratosis, superficial basal cell carcinoma, external genital warts (topical; per repurposing rationale — no formal Finland/TFDA license record on file)
Predicted New Indication	Pre-malignant neoplasm
TxGNN Prediction Score	99.92%
Evidence Level	L2
Finland Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed formal mechanism-of-action data was not returned by DrugBank in this evidence pack (flagged as a High-severity data gap, DG002). However, the evidence pack's own repurposing rationale documents imiquimod's known pharmacology: it is a TLR7 agonist that induces local interferon-α and cytokine release and activates cytotoxic T cells, driving immune-mediated clearance of abnormal epithelial cells. This mechanism underlies its established topical use for actinic keratosis, superficial basal cell carcinoma, and anogenital warts.

"Pre-malignant neoplasm" as a predicted indication is mechanistically close to the original use case rather than a distant repurposing leap — actinic keratosis and superficial BCC are themselves pre-malignant/early-malignant epithelial lesions. The predicted expansion covers other HPV- and UV-driven dysplastic conditions (cervical, vulvar, and anal intraepithelial neoplasia; lentigo maligna; Bowenoid papulosis) that share the same underlying biology: localized abnormal epithelial proliferation amenable to immune-mediated clearance via TLR7 activation. This is why the same drug class already has direct trial evidence across multiple anatomic sites rather than a single novel target.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02329171	Phase 3	Terminated	9	RCT of topical imiquimod for high-grade cervical intraepithelial neoplasia (CIN 2-3) as a non-invasive alternative to LLETZ excision; stopped early, underpowered
NCT01720407	Phase 3	Completed	259	Imiquimod as neoadjuvant treatment for lentigo maligna of the face, aiming to reduce excision size/risk of intralesional excision
NCT00175643	Phase 3	Completed	20	Imiquimod 5% cream, 3x/week for 1-2 cycles, for actinic keratoses on the head
NCT02242929	Phase 3	Unknown	145	Surgical excision vs. curettage + imiquimod for nodular basal cell carcinoma, non-inferiority RCT
NCT03233412	Phase 2	Completed	90	RCT of topical imiquimod efficacy in high-grade cervical intraepithelial lesions
NCT00941811	Phase 2	Completed	5	Explorative controlled study of imiquimod for vulvar intraepithelial neoplasia 2/3 (VIN) and anogenital warts, including immune escape mechanisms
NCT04219358	Phase 1	Terminated	49	RCT comparing 5% imiquimod, 0.05% imiquimod, and 0.05% nanoencapsulated imiquimod gel for actinic cheilitis (pre-malignant lip lesion)
NCT01229319	Phase 4	Unknown	20	Imiquimod 3.75% cream after cryotherapy for hypertrophic actinic keratoses on hands/forearms
NCT04883645	Early Phase 1	Completed	16	Neoadjuvant TLR7 agonist (imiquimod) immunotherapy in early-stage oral squamous cell carcinoma
NCT00142454	Phase 1	Completed	9	Imiquimod used as vaccine adjuvant in resected Stage IIB-III malignant melanoma (safety/immunogenicity)

Literature Evidence

PMID	Year	Type	Journal	Key Findings
23235673	2012	Cochrane Systematic Review	Cochrane Database Syst Rev	Interventions (including imiquimod) for anal intraepithelial neoplasia, an HPV-related pre-malignant condition
21491403	2011	Cochrane Systematic Review	Cochrane Database Syst Rev	Medical interventions (including imiquimod) for high-grade vulval intraepithelial neoplasia
26516853	2015	Review	Int J Mol Sci	Combined treatments with photodynamic therapy for non-melanoma skin cancer, including imiquimod's role
20505896	2010	Review	Skin Therapy Lett	Current management of actinic keratoses, including topical field therapies such as imiquimod
15584683	2004	Review	Semin Cutan Med Surg	Topical treatment strategies for non-melanoma skin cancer and precursor (pre-malignant) lesions
29500135	2018	Preclinical PK/PD	Urol Oncol	TLR7 agonists (imiquimod-related) evaluated for topical (pre-)malignant skin lesions and investigational intravesical use in bladder cancer
30284955	2019	Case Report	Int J STD AIDS	Successful treatment of high-grade vulval intraepithelial neoplasia with imiquimod 5% in a renal transplant recipient
18931984	2008	Case Report	Hautarzt	OCT imaging case with multiple pre-malignant lesions (actinic keratosis, SCC, Bowen's disease) resistant to topical treatment
15601490	2004	Case Report	Int J STD AIDS	Bowenoid papulosis of the penis (pre-malignant HPV-related lesion) successfully treated with topical imiquimod 5% cream

Finland Market Information

Imiquimod currently holds no marketing authorization in Finland (0 licenses on file; market status: Not Marketed). No product-level dosage form or approved-indication data is available from this evidence pack.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Two Cochrane systematic reviews and a completed Phase 3 RCT (lentigo maligna, n=259) support imiquimod's efficacy across several distinct pre-malignant epithelial conditions, and the mechanism is directly continuous with its established use in actinic keratosis and superficial BCC. However, no trial targets "pre-malignant neoplasm" as a unified indication — evidence is fragmented across CIN, VIN, AIN, actinic cheilitis, and lentigo maligna, and the pivotal CIN Phase 3 trial (NCT02329171) was terminated early and underpowered (n=9).

To proceed, the following is needed:

TFDA/Fimea package insert with warnings, contraindications, and DDI data (currently a Blocking data gap, DG001)
Confirmed formal mechanism-of-action documentation from DrugBank (DG002)
Clarification of whether Finland market entry is planned, given current "Not Marketed" status
A defined regulatory strategy for which specific pre-malignant subtype(s) (e.g., CIN, VIN, actinic cheilitis) to pursue, since "pre-malignant neoplasm" is not itself a registrable indication
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.